“Teva Pharmaceuticals has again defeated arguments that its generic version of the anti-overdose nasal spray Narcan violates patents on the drug, persuading a U.S. appeals court on Thursday to reject a lawsuit by Narcan maker Adapt Pharma.
The U.S. Court of Appeals for the Federal Circuit upheld a New Jersey court’s 2020 finding that the patents were invalid because earlier publications disclosed the same innovations.”
The Sterne, Kessler, Goldstein & Fox team representing Teva was led by J.C. Rozendaal, director and chair of the firm’s Trial & Appellate Group and includes fellow Directors: Paul Ainsworth, Michael Joffre, Adam LaRock, William Milliken, and Chandrika Vira.
To read the full article, please click the link below.
Read
Full Article
© 2022 Thomson Reuters. All rights reserved.
Stay in the Know
Receive insights from the most respected practitioners of IP law, straight to your inbox.
Subscribe for Updates